Raysearch Laboratories AB (publ) interim report January 1–June 30, 2015

HALF-YEAR (JANUARY–JUNE, 2015)

  · Net sales for the period amounted to SEK 165.1 M (105.8), of which
RayStation® accounted for SEK 106.6 M (50.9)
  · Profit after tax totaled SEK 22.4 M (5.9) and earnings per share were SEK
0.65 (0.17)
  · Operating profit amounted to SEK 31.0 M (8.4)
  · Cash flow was a negative SEK 2.3 M (neg: 11.3)
  · Order intake excluding service agreements amounted to SEK 158.3 M (101.6),
of which RayStation® accounted for SEK 124.4 M (59.1)

SECOND QUARTER (APRIL–JUNE, 2015)

  · Net sales for the period amounted to SEK 77.3 M (51.9), of which RayStation®
accounted for SEK 53.9 M (23.6)
  · Loss after tax totaled SEK 2.6 M (profit: 1.0) and loss per share was SEK
0.08 (earnings: 0.00)
  · Operating loss amounted to SEK 2.1 M (profit: 2.1)
  · Cash flow was a negative SEK 10.1 M (neg: 7.9)
  · Order intake excluding service agreements amounted to SEK 72.0 M (46.8), of
which RayStation® accounted for SEK 55.3 M (24.4)
  · RayStation® order backlog totaled SEK 33.8 M (66.5)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

  · The first proton therapy treatments with RayStation® for Mevion S250 in the
US
  · Texas Center for Proton Therapy, part of the national collaboration The US
Oncology Network, has selected RayStation®
  · Peter Thysell was appointed new CFO, Björn Hårdemark Deputy CEO, Kjell
Eriksson new Chief Science Officer and Victoria Sörving new General Counsel, and
all join executive management

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

  · RaySearch has secured a number of major orders from some of the world’s
largest and most respected cancer clinics, including the University of Texas MD
Anderson Cancer Center and the University of Florida Health Proton Therapy
Institute in the US, as well as Gustave Roussy in France
  · Long-term collaboration agreement signed with Accuray regarding the RayCare®
Oncology Information System

“Our success with RayStation® continues and the strong start to the year remains
unabated. During the first half of the year, revenues from RayStation® rose
approximately 129 percent to SEK 116.6 M (50.9). Overall, revenues rose 56.0
percent to SEK 165.1 M (105.8) and operating profit increased to SEK 31.0 M
(8.4), representing the highest-ever sales and earnings for the first half
-year,” says Johan Löf, CEO of RaySearch.

“In the third quarter, we have already secured several key orders from some of
the world’s largest and most respected cancer clinics, including MD Anderson and
the University of Florida Health Proton Therapy Institute in the US, and Gustave
Roussy in France. We secured these orders in direct competition with our main
competitors, which I consider firm confirmation that our system offers major
benefits,” says Johan Löf.

The information in the interim report is such that RaySearch is required to
disclose publicly in accordance with the Swedish Securities and Clearing
Operations Act and/or the Swedish Financial Instruments Trading Act. The
information was submitted for publication on August 28, 2015 at 7:45 a.m.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President
Tel: +46 8 510 530 00
johan.lof@raysearchlabs.com